Difference between revisions of "Doxorubicin (Adriamycin)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
| − | *[[ | + | *[[Adrenocortical carcinoma]] |
*[[Adult T-cell leukemia-lymphoma]] | *[[Adult T-cell leukemia-lymphoma]] | ||
*[[Anaplastic large cell lymphoma]] | *[[Anaplastic large cell lymphoma]] | ||
| + | *[[B-cell acute lymphoblastic leukemia]] | ||
*[[Basal cell carcinoma (BCC)]] | *[[Basal cell carcinoma (BCC)]] | ||
*[[Bladder cancer]] | *[[Bladder cancer]] | ||
| − | |||
*[[Breast cancer]] | *[[Breast cancer]] | ||
*[[Burkitt lymphoma]] | *[[Burkitt lymphoma]] | ||
*[[Chronic lymphocytic leukemia (CLL/SLL)]] | *[[Chronic lymphocytic leukemia (CLL/SLL)]] | ||
*[[Diffuse large B-cell lymphoma]] | *[[Diffuse large B-cell lymphoma]] | ||
| + | *[[Ewing's sarcoma]] | ||
*[[Follicular lymphoma]] | *[[Follicular lymphoma]] | ||
| − | *[[ | + | *[[Hepatocellular carcinoma]] |
*[[HIV-associated lymphoma]] | *[[HIV-associated lymphoma]] | ||
*[[Hodgkin lymphoma]] | *[[Hodgkin lymphoma]] | ||
| Line 27: | Line 28: | ||
*[[Mediastinal gray-zone lymphoma]] | *[[Mediastinal gray-zone lymphoma]] | ||
*[[Multiple myeloma]] | *[[Multiple myeloma]] | ||
| − | *[[ | + | *[[Osteosarcoma]] |
| + | *[[Pancreatic NET]] | ||
*[[Peripheral T-cell lymphoma]] | *[[Peripheral T-cell lymphoma]] | ||
| + | *[[Post-transplant lymphoproliferative disorder]] | ||
*[[Primary mediastinal B-cell lymphoma]] | *[[Primary mediastinal B-cell lymphoma]] | ||
*[[Renal cancer]] | *[[Renal cancer]] | ||
*[[Soft tissue sarcoma]] | *[[Soft tissue sarcoma]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| + | *[[Squamous cell carcinoma (SCC)]] | ||
*[[Thymoma]] | *[[Thymoma]] | ||
*[[Transformed lymphoma]] | *[[Transformed lymphoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
*[[Uterine cancer]] | *[[Uterine cancer]] | ||
| + | *[[Vascular sarcoma]] | ||
| + | *[[Waldenström macroglobulinemia]] | ||
</div> | </div> | ||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx Doxorubicin (Adriamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx Doxorubicin (Adriamycin) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx Doxorubicin (Adriamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx Doxorubicin (Adriamycin) patient drug information (Chemocare)]</ref> | ||
| Line 49: | Line 54: | ||
==Also known as== | ==Also known as== | ||
| + | *'''Generic name:''' hydroxydaunorubicin | ||
| + | *'''Brand names:''' | ||
{| border="1" style="text-align:center;" | {| border="1" style="text-align:center;" | ||
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | !colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms''' | ||
| Line 55: | Line 62: | ||
|Adriacept | |Adriacept | ||
|Adriacin | |Adriacin | ||
| − | |Adriamycin | + | |Adriamycin |
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Adriblastin | |Adriblastin | ||
|Adriblastina | |Adriblastina | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Adriblastine | |Adriblastine | ||
| + | |Adricept | ||
|- | |- | ||
| − | |||
| − | |||
| − | |||
| − | |||
|Adricin | |Adricin | ||
|Adrim | |Adrim | ||
|Adrimedac | |Adrimedac | ||
|Adrosal | |Adrosal | ||
| − | |||
|Antraciclin | |Antraciclin | ||
|Biorrub | |Biorrub | ||
|Biorubina | |Biorubina | ||
|Cadria | |Cadria | ||
| + | |- | ||
|Carcinocin | |Carcinocin | ||
|Cloridrato DE | |Cloridrato DE | ||
|Doxorrubicina Colhidrol | |Doxorrubicina Colhidrol | ||
|Daxotel | |Daxotel | ||
| − | |||
|Deldoxin | |Deldoxin | ||
|Dicladox | |Dicladox | ||
|Dobicin | |Dobicin | ||
|Dobixin | |Dobixin | ||
| + | |- | ||
|Doxo | |Doxo | ||
|Doxobin | |Doxobin | ||
|Doxo Cell | |Doxo Cell | ||
|Doxocris | |Doxocris | ||
| − | |||
|Doxokebir | |Doxokebir | ||
|Doxolem | |Doxolem | ||
| − | |||
|Doxonolver | |Doxonolver | ||
|Doxor | |Doxor | ||
| + | |- | ||
|Doxorrubicina | |Doxorrubicina | ||
|Doxoruben | |Doxoruben | ||
|Doxorubicina | |Doxorubicina | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Doxorubicine | |Doxorubicine | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
|Doxorubicinum | |Doxorubicinum | ||
|Doxorubin | |Doxorubin | ||
|Doxotec | |Doxotec | ||
|Doxtie | |Doxtie | ||
| + | |- | ||
|Duxocin | |Duxocin | ||
|Evacet | |Evacet | ||
| − | |||
|Farmiblastina | |Farmiblastina | ||
|Fauldoxo | |Fauldoxo | ||
|Flavicina | |Flavicina | ||
| − | | | + | |Ifadox |
| − | | | + | |Kemodoxa |
|Lipodox | |Lipodox | ||
| + | |- | ||
|Lyphidox | |Lyphidox | ||
|Myocet | |Myocet | ||
| − | |||
|Nagun | |Nagun | ||
|Neoxane | |Neoxane | ||
| Line 157: | Line 121: | ||
|Onkodox | |Onkodox | ||
|Onkostatil | |Onkostatil | ||
| + | |- | ||
|Pallagicin | |Pallagicin | ||
|Ranxas | |Ranxas | ||
| − | |||
|Rastocin | |Rastocin | ||
|Ribodoxo | |Ribodoxo | ||
| − | |||
|Roxorin | |Roxorin | ||
|Rubex | |Rubex | ||
| − | |||
| − | |||
|Varidoxo | |Varidoxo | ||
| − | |||
|Zodox | |Zodox | ||
|} | |} | ||
| Line 182: | Line 142: | ||
[[Category:Topoisomerase inhibitors]] | [[Category:Topoisomerase inhibitors]] | ||
| − | [[Category: | + | [[Category:Adrenocortical carcinoma medications]] |
[[Category:Adult T-cell leukemia-lymphoma medications]] | [[Category:Adult T-cell leukemia-lymphoma medications]] | ||
[[Category:Anaplastic large cell lymphoma medications]] | [[Category:Anaplastic large cell lymphoma medications]] | ||
| + | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
[[Category:Basal cell carcinoma (BCC) medications]] | [[Category:Basal cell carcinoma (BCC) medications]] | ||
[[Category:Bladder cancer medications]] | [[Category:Bladder cancer medications]] | ||
| − | |||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:Burkitt lymphoma medications]] | [[Category:Burkitt lymphoma medications]] | ||
[[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
| + | [[Category:Ewing's sarcoma medications]] | ||
[[Category:Follicular lymphoma medications]] | [[Category:Follicular lymphoma medications]] | ||
| − | [[Category: | + | [[Category:Hepatocellular carcinoma medications]] |
[[Category:HIV-associated lymphoma medications]] | [[Category:HIV-associated lymphoma medications]] | ||
[[Category:Hodgkin lymphoma medications]] | [[Category:Hodgkin lymphoma medications]] | ||
| Line 201: | Line 162: | ||
[[Category:Mediastinal gray-zone lymphoma medications]] | [[Category:Mediastinal gray-zone lymphoma medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
| − | [[Category: | + | [[Category:Osteosarcoma medications]] |
| + | [[Category:Pancreatic NET medications]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
| + | [[Category:Post-transplant lymphoproliferative disorder medications]] | ||
[[Category:Primary mediastinal B-cell lymphoma medications]] | [[Category:Primary mediastinal B-cell lymphoma medications]] | ||
[[Category:Renal cancer medications]] | [[Category:Renal cancer medications]] | ||
[[Category:Soft tissue sarcoma medications]] | [[Category:Soft tissue sarcoma medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
| + | [[Category:Squamous cell carcinoma (SCC) medications]] | ||
[[Category:Thymoma medications]] | [[Category:Thymoma medications]] | ||
[[Category:Transformed lymphoma medications]] | [[Category:Transformed lymphoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
[[Category:Uterine cancer medications]] | [[Category:Uterine cancer medications]] | ||
| + | [[Category:Vascular sarcoma medications]] | ||
| + | [[Category:Waldenström macroglobulinemia medications]] | ||
[[Category:Drugs FDA approved in 1974]] | [[Category:Drugs FDA approved in 1974]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 22:30, 21 January 2018
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Adrenocortical carcinoma
- Adult T-cell leukemia-lymphoma
- Anaplastic large cell lymphoma
- B-cell acute lymphoblastic leukemia
- Basal cell carcinoma (BCC)
- Bladder cancer
- Breast cancer
- Burkitt lymphoma
- Chronic lymphocytic leukemia (CLL/SLL)
- Diffuse large B-cell lymphoma
- Ewing's sarcoma
- Follicular lymphoma
- Hepatocellular carcinoma
- HIV-associated lymphoma
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Mantle cell lymphoma
- Marginal zone lymphoma
- Mediastinal gray-zone lymphoma
- Multiple myeloma
- Osteosarcoma
- Pancreatic NET
- Peripheral T-cell lymphoma
- Post-transplant lymphoproliferative disorder
- Primary mediastinal B-cell lymphoma
- Renal cancer
- Soft tissue sarcoma
- Small cell lung cancer
- Squamous cell carcinoma (SCC)
- Thymoma
- Transformed lymphoma
- Transplant conditioning regimens
- Uterine cancer
- Vascular sarcoma
- Waldenström macroglobulinemia
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/7/1974: Initial FDA approval
- 5/8/2003: Earliest date with label information at Drugs @ FDA: "Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Also known as
- Generic name: hydroxydaunorubicin
- Brand names:
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Adriablastina | Adriacept | Adriacin | Adriamycin | Adriblastin | Adriblastina | Adriblastine | Adricept |
| Adricin | Adrim | Adrimedac | Adrosal | Antraciclin | Biorrub | Biorubina | Cadria |
| Carcinocin | Cloridrato DE | Doxorrubicina Colhidrol | Daxotel | Deldoxin | Dicladox | Dobicin | Dobixin |
| Doxo | Doxobin | Doxo Cell | Doxocris | Doxokebir | Doxolem | Doxonolver | Doxor |
| Doxorrubicina | Doxoruben | Doxorubicina | Doxorubicine | Doxorubicinum | Doxorubin | Doxotec | Doxtie |
| Duxocin | Evacet | Farmiblastina | Fauldoxo | Flavicina | Ifadox | Kemodoxa | Lipodox |
| Lyphidox | Myocet | Nagun | Neoxane | Nuaze | Oncodria | Onkodox | Onkostatil |
| Pallagicin | Ranxas | Rastocin | Ribodoxo | Roxorin | Rubex | Varidoxo | Zodox |
References
Categories:
- Drug index
- Intravenous medications
- Vesicant chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Adrenocortical carcinoma medications
- Adult T-cell leukemia-lymphoma medications
- Anaplastic large cell lymphoma medications
- B-cell acute lymphoblastic leukemia medications
- Basal cell carcinoma (BCC) medications
- Bladder cancer medications
- Breast cancer medications
- Burkitt lymphoma medications
- Chronic lymphocytic leukemia (CLL/SLL) medications
- Diffuse large B-cell lymphoma medications
- Ewing's sarcoma medications
- Follicular lymphoma medications
- Hepatocellular carcinoma medications
- HIV-associated lymphoma medications
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Mantle cell lymphoma medications
- Marginal zone lymphoma medications
- Mediastinal gray-zone lymphoma medications
- Multiple myeloma medications
- Osteosarcoma medications
- Pancreatic NET medications
- Peripheral T-cell lymphoma medications
- Post-transplant lymphoproliferative disorder medications
- Primary mediastinal B-cell lymphoma medications
- Renal cancer medications
- Soft tissue sarcoma medications
- Small cell lung cancer medications
- Squamous cell carcinoma (SCC) medications
- Thymoma medications
- Transformed lymphoma medications
- Transplant medications
- Uterine cancer medications
- Vascular sarcoma medications
- Waldenström macroglobulinemia medications
- Drugs FDA approved in 1974
- WHO Essential Cancer Medicine